多発性骨髄腫患者におけるダラツムマブ皮下投与時の有害事象に対するジフェンヒドラミンとレボセチリジン前処置の比較

• 資料種別: 記事
• タイトル: 多発性骨髄腫患者におけるダラツムマブ皮下投与時の有害事象に対するジフェンヒドラミンとレボセチリジン前処置の比較
• 著者標目: 末廣 直哉; 長島 彩乃; 西川 はる; 鈴川 真由; 櫻井 洋臣; 村松 博; 青森 達; 大谷 壽一
• 出版年月日等: 2023-08-10
• 出版年（W3CDTF）: 2023-08-10
• タイトル（掲載誌）: 医療薬学
• 巻号年月日等（掲載誌）: 49 8
• 掲載巻: 49
• 掲載号: 8
• 掲載ページ: 303-309
• 掲載年月日（W3CDTF）: 2023-08-10
• ISSN（掲載誌）: 1346342X
• ISSN-L（掲載誌）: 1346342X
• 出版事項（掲載誌）: Japanese Society of Pharmaceutical Health Care and Sciences
• 本文の言語コード: ja
• 件名標目: daratumumab; antihistamine; levocetirizine; infusion reaction; drowsiness
• 対象利用者: 一般
• DOI: 10.5649/jjphcs.49.303; https://doi.org/10.5649/jjphcs.49.303
• 関連情報（URI）: https://www.jstage.jst.go.jp/article/jjphcs/49/8/49_303/_pdf; https://search.jamas.or.jp/link/ui/2023282912
• 参照: Cetirizine versus diphenhydramine in the prevention of chemotherapy-related hypersensitivity reactions; https://cir.nii.ac.jp/crid/1360020001687747456; Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites; https://cir.nii.ac.jp/crid/1360292619463358848; Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma; https://cir.nii.ac.jp/crid/1360301475091635328; Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial; https://cir.nii.ac.jp/crid/1360855569810943488; Pharmacology of antihistamines; https://cir.nii.ac.jp/crid/1360855570735241472; Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications; https://cir.nii.ac.jp/crid/1360864423858448256; Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma; https://cir.nii.ac.jp/crid/1361981470526518144; Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study; https://cir.nii.ac.jp/crid/1362262943877346432; Efficacy of diphenhydramine vs desloratadine and placebo in patients with moderate-to-severe seasonal allergic rhinitis; https://cir.nii.ac.jp/crid/1362544418447561856; Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma; https://cir.nii.ac.jp/crid/1362544421033650944; Evaluation of the safety and efficacy of daratumumab outside of clinical trials; https://cir.nii.ac.jp/crid/1363951794767046400; Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial; https://cir.nii.ac.jp/crid/1364233269854961664; 日本人の再発または難治性多発性骨髄腫におけるDaratumumabの安全性に関する後方視的検討とInfusion Related Reaction発現リスク因子の探索; https://cir.nii.ac.jp/crid/1390286981358561536; フェキソフェナジンあるいはベポタスチンの前投薬によるリツキシマブ投与時のinfusion reaction発現抑制効果; https://cir.nii.ac.jp/crid/1390848250127668480
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Japan Link Center; https://japanlinkcenter.org/top; Crossref; https://www.crossref.org

• 要約等: <p>Subcutaneous daratumumab DARA-SC is superior to intravenous daratumumab with a significantly shorter treatment time for multiple myeloma. To preven...